The objective was to develop a risk scoring tool which predicts respiratory syncytial virus hospitalisation (RSVH) in moderate-late preterm infants (32-35 weeks' gestational age) in the Northern Hemisphere.
2009. 3 Moderate-late preterm infants (defined as 32 to 33-35 weeks' completed gestation at birth [wGA] ) are at higher risk of severe RSV LRTI and greater morbidity than full-term infants. 4 Studies show that they also incur higher healthcare utilisation costs over the first 2 years of life, 5, 6 and more frequent recurrent wheezing through 6 years of age compared to non-RSV hospitalised infants. 7 A pooled-analysis of seven prospective, observational studies comprising 7820 infants born at 33-35 wGA during the RSV season, reported an incidence rate of 3.4% for first confirmed RSV hospitalisation (RSVH), with 22.2% requiring intensive care and 12.7% needing mechanical ventilation. 8 At present, palivizumab is the only licensed therapy for reducing RSVH rates, 9, 10 though there are several new monoclonal antibodies on the horizon. 11, 12 In order to effectively manage healthcare budgets, sub-populations of moderate-late preterms at particular risk need to be identified for intervention. 13, 14 Large studies across the Northern Hemisphere have established risk factors associated with severe RSV LRTI in moderate-late preterm infants, including those related to RSV exposure (eg, daycare attendance), biological factors (eg, male sex), and social/environmental factors (eg, exposure to tobacco smoke). [15] [16] [17] [18] [19] [20] [21] Several risk scoring tools (RST) using data from these studies, identify moderate-late preterm infants at risk for RSVH in order to target RSV prophylaxis judiciously. 13, 14, [22] [23] [24] The models demonstrate good sensitivity (∼70%) and specificity (∼70%), 13, 14, 22, 23 with the Canadian model proven to be cost-effective in clinical practice. 25, 26 A model for general applicability across multiple countries has not been developed.
The objective of the current study was to use a pooled dataset of studies to develop a simple and validated risk factor tool with improved performance, applicable across the Northern Hemisphere.
| METHODS

| Pooled dataset used for modelling
Individual patient-linked data from six prospective, observational studies across the Northern Hemisphere were used to develop the predictive model underpinning the RST: 'Risk Factors Linked to Respiratory Syncytial Virus Infection Requiring Hospitalization in Premature Infants Study' (FLIP-2, Spain) 17 ; 'RISK' (the Netherlands) 13 ;
'Pediatric Investigators Collaborative Network on Infections in
Canada' (PICNIC, Canada) 15 ; 'Italian National Birth Cohort' (IBC, Italy) 19 ; 'Respiratory Syncytial Virus (RSV) Respiratory Events Among Preterm Infants Outcomes and Risk Tracking Study' (REPORT, USA) 18 ;
and 'Predictors Associated with RSV Hospitalization in Nonprophylaxed, Premature Infants' (PONI, multinational) 20 (Table 1) . These studies had been previously identified by a systematic review of the literature undertaken in 2015. 8 The key inclusion criteria for studies were: multicentre, observational, prospective design; assessed >1000 moderate-late preterm (32-35 wGA) infants at risk for severe RSV disease (defined as the need for hospitalisation); included infants with laboratory-confirmed RSV infection; and ≤15% of infants received palivizumab prophylaxis (to ensure a standardised and unbiased population). An updated search of the literature (to 18 December 2017) identified no additional studies meeting the inclusion criteria.
| Data extraction, recasting, verification and analysis
Data for infants (≤1 year) born at 32 weeks and 0 days (32 0 ) to 35 weeks and 6 days (35 6 ) gestation were extracted from each study, including information on first confirmed RSVH and corresponding risk factors. To ensure homogeneity, infants were excluded if they were born at <32 0 or >35 6 wGA, had received RSV prophylaxis, or had a relevant comorbidity (eg, congenital heart disease, bronchopulmonary dysplasia/chronic lung disease). All data were anonymised. To ensure sufficient data for analysis, the collection/recording of a risk variable in at least four studies was a requisite for inclusion in the pooled dataset.
Included risk factors were recast, where necessary, into a common format across studies. To verify each study's data before inclusion, the extracted datasets were checked and approved by key study investigators and personnel (XCE, MB, BP, ML, EJA; also see Acknowledgments section). The quantity of data available for three risk factor variables from each dataset were further confirmed against the original study publication. A heterogeneity test for the dichotomous variables present in all contributory datasets was performed by comparing odds ratios (ORs) using the Breslaw-Day method. For categoric variables (>2 categories), data were converted to ranks and analysis of variance (ANOVA) conducted on the differences from mean rank in hospitalised and non-hospitalised infants. Heterogeneity for continuous variables was assessed by comparing the significance of difference between hospitalised and non-hospitalised infants using parametric t-test. Statistical significance of individual variables in the pooled dataset was assessed by two-tailed t-test (parametric data) and
Mann-Whitney U-test and Mantel-Haenzel test (categoric data).
| Development of the predictive model
Logistic regression was used to develop a preliminary risk factor model that included all risk factors in the pooled dataset. RSVH was the dependent variable and the risk factors were the covariates. Where risk factor data were missing for an infant, average values for that dataset were used, or when all values for a particular risk factor were missing from a dataset, the combined data average were applied.
Alternative approaches using a new category for a missing value or neutral, non-discriminatory values were also tested. 
| Validation of the final model
Three main approaches were used to validate the final model. First, the model was generated in the FLIP-2, 17 PICNIC, 15 RISK 13 and PONI 20 datasets and compared to the published models for those studies (IBC 19 and REPORT 18 do not have published models). 13, 22, 24 Second, 100-fold bootstrapping validation was performed on the pooled dataset. 28 Estimation Measure for RSVH in Ireland study (RSV-PREMI), 21 which was identified in the same systematic review as the studies in the pooled dataset (Table 1) . 8 Data were verified by study personnel (MS-P and Acknowledgments), including three variables checked against the study publication, and heterogeneity assessed as previously described.
The model was tested in two ways against the RSV-PREMI data: (i) generating a model from the RSV-PREMI data itself using the same risk factors as for the final model and (ii) the coefficients from the pooled dataset were applied to the RSV-PREMI data. For both analyses, predictive accuracy was assessed by AUROC.
| Development of the RST
To convert the final model into a RST, the logistic regression coefficient(s) for each variable was assigned a rounded multiplier with a positive value. The rounded multiplier provides a measure of the influence of a particular risk factor on the probability of RSVH relative to that of the other risk factors in the model (the higher the value, the greater the influence). The sum of the rounded multipliers, taking into consideration any categorical variables that may have more than one multiplier, represented the maximum score of the tool.
Cut-off scores for low-, moderate-and high-risk groups were determined based on RSVH rates of <2%, 2-10% and >10%, respectively, in line with the RSTs developed in Canada 22 and the Netherlands 13, 14 (the FLIP-2 24 and PONI 20 models did not include cutoffs). The RSVH rate was also plotted against the risk score to determine if there were any apparent inflections in the curve from which to refine the cut-off values. A very high-risk group was defined by examining a score that would limit the RST to capturing TABLE 1 Overview of studies included in developing and validating the risk factor model 
| Transparency of reporting
The Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement was followed for this manuscript ( Supplementary Table S1 ). 30 The TRIPOD statement provides a framework for the full and clear reporting of a prediction model study, such that risk of bias and potential usefulness can be adequately assessed. 30 3 | RESULTS
| Pooled dataset
The six studies (FLIP-2, 17 RISK, 13 PICNIC, 15 IBC, 19 REPORT, 18 PONI 20 ) contained individual patient-linked data collected from 2000 to 2014 for a total of 15 862 infants, of whom 13 475 were born between 32 0 and 35 6 wGA and met the inclusion criteria for the pooled dataset ( Table 1) .
The primary reasons for exclusion were birth ≥36 wGA (n = 1184), receiving RSV prophylaxis (n = 693), and having an exclusionary comorbidity (n = 490). Each study contributed at least 1000 infants to the pooled dataset, with all providing data for infants born at 33-35 wGA and three studies contributing data as well for 32 wGA infants (FLIP-2, 17 RISK, 13 REPORT 18 ). The overall distribution by wGA was 32 wGA (6.9%), 33 wGA (24.4%), 34 wGA (38.1%) and 35 wGA (30.7%).
Of the 13 475 infants in the pooled dataset, 484 (3.6%) had a confirmed RSVH within the first year of life. A total of 18 possible risk factors for RSVH were present in four of the six studies and were recast to a common format ( Supplementary Table S2 ). Prior to inclusion in the pooled dataset, the extracted data for each study were confirmed and verified against the published data with no apparent discrepancies ( Supplementary Table S3 ). Heterogeneity tests revealed no significant differences for 11 of the 12 risk factor variables present in all six datasets; smokers in the household differed significantly (P = 0.04) between studies, with rates varying between 4 and 67% across studies ( Supplementary Table S4 ).
| Risk factor model
The final logistic regression model comprised three variables, combining a total of five risk factors: birth between 3 months before and 2 months after season start date; smokers in the household and/ or maternal smoking whilst pregnant; and siblings (excluding multiple births) and/or daycare attendance (recorded as 'planned', reflecting how the RST would be used in practice). Treating all risk factors as categorical covariates (ie, assigning into groups and treating as nonlinear scales), the derived model had an AUROC of 0.773 (95% confidence interval [CI] 0.753-0.792) and a maximum sensitivity and specificity of 0.689 and 0.730, respectively (Figure 1 ). The most predictive variable was the combination of siblings and daycare, though age relative to the start of the RSV season was the single most powerful risk factor ( Table 2) . Refining the siblings variable to pre-school age (<6 years), which is a highly significant risk factor for RSVH, 18, 20 increased the AUROC minimally to 0.775. It was considered more practical to exclude a sibling age criterion, particularly when 'pre-school age' is defined differently across countries. Substituting (any) siblings for a broader 'crowding' variable of >4 in the household including infant, >4 being the most predictive cut-off, or adding this variable to the model did not increase overall predictive accuracy (AUROC 0.764 for both substitution and addition). Unlike the other five datasets, PONI recorded only month (not day) of birth. 20 The age variable birth between 3 months before and 2 months after season start date was intended to simplify the calculated 13 weeks before to 8.5 weeks after the start of the RSV season. The use of a new category or imputation of neutral, nondiscriminatory values for missing data resulted in models with similar discrimination (new category, AUROC 0.773; non-discriminatory, AUROC 0.770), confirming the absence of unrecognised bias associated with using average values.
| Validation of the risk factor model
| Generation of the model in individual datasets
Generating the final model in the individual datasets resulted in functions that were more powerful in FLIP-2: AUROC 0.762 versus 0.687, 24 respectively, and in the other cases was within 3-12% of the predictive power of the published models (PICNIC: 0.673 vs 0.762 22 ; RISK: 0.680 vs 0.703; 13 PONI: 0.701 vs 0.755 20 ) ( Supplementary   Table S5 ). 
| Internal validation
| External validation
RSV-PREMI 21 included 1078 infants born 32 0 -35 6 wGA of whom 46 (4.3%) were hospitalised with RSV LRTI in the first year of life ( Table 1) .
All risk factors comprising the final model were available in RSV-PREMI and were recast in exactly the same format as the pooled dataset.
Analysis revealed no apparent discrepancies between the extracted and published data for RSV-PREMI ( Supplementary Table S3 ). The risk factors in the final model were shown to behave similarly within RSV-PREMI and the pooled dataset ( Supplementary Table S4 ).
Generating a model in the RSV-PREMI 21 
| RST
Converting the logistic regression coefficients for each variable in the final model into rounded multipliers resulted in a maximum risk score of 56 (Table 2 and Figures 2A and 2B) . The RST was created as a nomogram with a score ≤19 representing a low-risk of RSVH (average risk 1.0%), 20-45 representing a moderate-risk (average risk 3.3%) and ≥50 representing high-risk (average risk 9.5%). Plotting the RSVH rate against the risk score resulted in a curve with a natural inflection at a score of ∼45 (Supplementary Figure S3 ). This was set as the medium/ high-risk boundary. The high-risk group identified 62.0% of all RSVHs whilst selecting 23.6% of the total study population. The corresponding figures for the moderate-and low-risk groups were 23.2%/25.1% and 14.8%/51.3%, respectively (Figure 3) . The high-and moderate-risk groups both had a significantly higher RSVH risk than the low risk group (OR 10.1, 95%CI 7.9-12.9, P < 0.001; and OR 3.3, 95%CI 2.5-4.4, P < 0.001, respectively; combined high-and moderate-risk: OR 6.4, 95%CI 5.1-8.2, P < 0.001). The NNT for the high-risk group was 15.3, while the combined high-and moderate-risk group had a NNT of 33.3.
A very high-risk group was defined as a score of 56, which captured 39.3% of RSVHs whilst selecting 11.9% of the total population, with a corresponding NNT of 10.8. and can be applied effectively across the Northern Hemisphere.
| DISCUSSION
The RST has a scale of 0-56 with defined cut-off scores for low-(≤19), moderate-(20-45) and high-risk (≥50) infants. The cumulative RSVH risk was 3.6% (484/13 475) in the pooled dataset, with the combined moderate-and high-risk groups being 6.3%, the high-risk group 9.5% and the very high-risk group (score of 56) 11.9%. The NNT for the combined high-and moderate-risk groups was 33.3, which falls to 15.3 in the high-risk group and 10.8 for very high-risk infants. A balance must be struck between the cost-effectiveness of palivizumab versus potential therapeutic benefits, with the very high-risk group having a compelling NNT, but missing 60% of predicted RSVHs.
Ultimately, the final decision regarding appropriate cut-offs should be made locally, taking into consideration the overall risk-cost-benefit relative to each clinical setting.
The validated RST described herein is simple and has good predictive accuracy to assess RSVH risk in moderate-late preterm infants. Developing the tool from six datasets confirms its predictive capabilities, generalisability and applicability across the Northern Hemisphere. The RST is a powerful instrument to determine RSVH risk and direct RSV therapies cost-effectively to the most vulnerable moderate-late preterm infants.
